PHARMACEUTICAL PREPARATIONS
Turn Therapeutics Inc. Common Stock
TTRX
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
Valuation
- Market capitalization
- $261.4M
- Price / earnings
- —
- Price / book
- 45.92×
- Price / sales
- —
- EV / sales
- —
- EV / EBITDA
- -36.77×
Profitability
- Earnings per share
- -$0.42
- Return on assets
- -78.12%
- Return on equity
- -224.39%
- Dividend yield
- 0%
Liquidity and leverage
- Debt / equity
- 1.09×
- Current ratio
- 3.19×
- Quick ratio
- 3.19×
- Cash ratio
- 2.98×
Cash flow
- Price / cash flow
- —
- Price / free cash flow
- —
- Free cash flow
- -$5.28M
Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q3 FY2026 Sep 30, 2026 | Q2 FY2026 Jun 30, 2026 | Q1 FY2026 Mar 31, 2026 | Q4 FY2025 Dec 31, 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| Selling, general and administrative | $1.38M | $1.15M | $1.14M | $2.16M |
| Research and development | $605.2K | $475.06K | $109.43K | $34.93K |
| Total operating expenses | $1.98M | $1.63M | $1.25M | $2.19M |
| Operating income | -$1.98M | -$1.63M | -$1.25M | -$2.19M |
| Interest expense | -$341.21K | -$241.36K | $0 | $0 |
| Income before taxes | -$6.23M | -$5.85M | -$970.97K | $279.07K |
| Income taxes | $0 | $0 | $0 | $0 |
| Net income | -$6.23M | -$5.85M | -$970.97K | $279.07K |
| Net income attributable to common shareholders | -$6.23M | -$5.85M | -$970.97K | $279.07K |
| EBITDA | -$1.94M | -$1.64M | -$1.23M | -$2.18M |
| Basic earnings per share | -$0.21 | -$0.20 | -$0.03 | $0.01 |
| Diluted earnings per share | -$0.21 | -$0.20 | -$0.03 | $0.01 |
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
No stock split records found.